BAYRY: Bayer insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
15 institutions reported holding $93.52M of Bayer on Form 13F (16 the quarter before). 0 opened a new position and 1 sold out. Shares held by institutions: same.
| Largest holders | Shares | Value |
|---|---|---|
| KAHN BROTHERS GROUP INC | 6,518,603 | $89.31M |
| GREAT LAKES ADVISORS, LLC | 126,119 | $1.73M |
| RHUMBLINE ADVISERS | 68,922 | $944K |
| GAMMA Investing LLC | 41,204 | $564K |
| ATLAS CAPITAL ADVISORS INC. | 34,746 | $476K |
| CHICAGO TRUST Co NA | 20,097 | $278K |
| PNC Financial Services Group, Inc. | 3,203 | $44K |
| First Command Advisory Services, Inc. | 2,971 | $41K |
| Westside Investment Management, Inc. | 2,878 | $39K |
| Salomon & Ludwin, LLC | 2,668 | $37K |
Clinical trial readouts
4 Phase 2 or 3 trials by Bayer with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-09-15 | BAY2599023 (DTX201) | Hemophilia A | Phase 1/2 | 11 | Completed | NCT03588299 |
| 2027-04-10 (est.) | Finerenone (Kerendia, BAY94-8862) | Chronic Kidney Disease | Phase 3 | 219 | Enrollment complete | NCT05196035 |
| 2027-07-30 (est.) | Darolutamide (BAY1841788, Nubeqa) | Biochemically Recurrent Prostate Cancer | Phase 3 | 985 | Enrollment complete | NCT05794906 |
| 2027-10-28 (est.) | Sevabertinib | Advanced Non-small Cell Lung Cancer, HER2 Mutation | Phase 3 | 444 | Recruiting | NCT06452277 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.